Back to top

Analyst Blog

Nektar Therapeutics (NKTR - Analyst Report) announced disappointing initial top-line results from a phase II study on NKTR-181. The candidate is being developed for the treatment of moderate-to-severe chronic pain in patients suffering from osteoarthritis of the knee.

The phase II, double-blind, placebo-controlled, randomized withdrawal study evaluated the efficacy, safety and tolerability of NKTR-181. Patients entering this phase of the study were randomized equally to either continue to receive NKTR-181 or placebo.

Although patients treated with NKTR-181 showed a reduction in pain scores throughout the randomized phase of the study, patients under placebo failed to show the expected increase in pain scores observed in enriched enrolment, randomized withdrawal studies of similar nature. The company stated in its press release that the lack of a placebo rebound was unusual. As a result, the study failed to meet its primary objective.

The primary objective of the study was based on the average change in pain scores from pre-randomization baseline to the end of the double-blind, randomized therapy period of the study. The failure to meet its primary end point is indeed disappointing.

Nektar also intends to review its placebo arm of the study and will be designing other pivotal trials on the candidate as well. We remind investors that NKTR-181 currently enjoys fast track designation in the U.S. for the treatment of moderate-to-severe chronic pain.

We expect the share price of Nektar to be negatively impacted by the news. We also remind investors that the market for chronic pain has big companies like Johnson & Johnson (JNJ - Analyst Report) and Pfizer Inc. (PFE - Analyst Report).

Nektar presently carries a Zacks Rank #4 (Sell). Stocks such as Actelion Ltd. (ALIOF) currently look attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%